Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144379 | 0.83 | TPMT (0.51) | TPMTKDM4EALDH1A1HSD17B10MCL1 | |
| SCHEMBL5142275 | 0.81 | TPMT (0.42) | TPMTKDM4EALDH1A1HSD17B10MCL1 | |
| SCHEMBL11407764 | 0.80 | ALDH1A1 (0.37) | TPMTALDH1A1 | |
| SCHEMBL31232360 | 0.76 | TPMT (0.39) | TPMTALDH1A1 | |
| SCHEMBL25779937 | 0.76 | TPMT (0.39) | TPMTALDH1A1 | |
| SCHEMBL28692659 | 0.75 | MEN1 (0.35) | TPMTALDH1A1 | |
| SCHEMBL5144281 | 0.73 | KDM4E (0.32) | TPMTKDM4EALDH1A1HSD17B10TAS1R3 | |
| SCHEMBL28279501 | 0.72 | ALDH1A1 (0.37) | TPMTALDH1A1 | |
| SCHEMBL10826112 | 0.71 | LMNA (0.39) | TPMTALDH1A1CYP2C9 | |
| SCHEMBL9451092 | 0.71 | POLB (0.32) | TPMTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423136-A4 | POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULATING HALF-LIVES | EPIX PHARM INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7186797-B2 | Polypeptide conjugates with extended circulating half-lives | EPIX PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186797-B2 | Polypeptide conjugates with extended circulating half-lives | EPIX PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186797-B2 | Polypeptide conjugates with extended circulating half-lives | EPIX PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20040254119-A1 | Polypeptide conjugates with extended circulating half-lives | EPIX PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| EP-1423136-A1 | POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULATING HALF-LIVES | Epix Medical, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003013573-A1 | POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULATING HALF-LIVES | EPIX MEDICAL, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254119-A1 | Polypeptide conjugates with extended circulating half-lives | ALB, TTR, SHBG | TPMT 3599/4885KDM4E 4663/4885ALDH1A1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.